

Abbott Laboratories(USD) ABT

Last Close \$ 43.71
Sales \$Mil \$22,162
Mkt Cap \$Mil \$65,818
Industry Drug Manufacturers - USD
Currency Specialty & Generic

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

100 Abbott Park Road
 Abbott Park, IL 60064-6400
 Phone: +1 847 937-6100
 Website: <http://www.abbott.com>

Growth Rates Compound Annual					
Grade: D	1 Yr	3 Yr	5 Yr	10 Yr	
Revenue %	1.7	-14.7	-5.9	1.1	
Operating Income %	38.8	-24.4	-14.3	-2.3	
Earnings/Share %	316.7	-20.4	-13.1	-1.5	
Dividends %	-72.1	-31.2	-16.8	-5.4	
Book Value/Share %	-4.1	3.5	7.6	6.9	
Stock Total Return	17.2	21.7	13.4	9.3	
+/- Industry	-29.0	-10.9	-8.0	-3.9	
+/- Market	1.3	0.3	-2.0	1.5	


Profitability Analysis				
Grade: D	Current	5 Yr Avg	Ind	Mkt
Return on Equity %	8.5	20.4	6.5	21.2
Return on Assets %	4.5	8.4	2.4	8.2
Revenue/Employee \$K	321.2	358.4	—	1029.2
Fixed Asset Turns	3.8	3.9	4.2	7.0
Inventory Turns	3.7	3.9*	2.4	11.9
Gross Margin %	54.4	56.7	55.9	44.1
Operating Margin %	13.1	14.6	11.6	20.9
Net Margin %	8.9	16.7	5.2	14.2
Free Cash Flow/Rev %	13.4	21.3	11.7	13.1
R&D/Rev %	6.6	8.9	8.7	—

Financial Position (USD)			
Grade: A	12-13 \$Mil	09-14 \$Mil	
Cash	3475	3613	
Inventories	2693	2696	
Receivables	3986	3618	
Current Assets	19247	16464	
Fixed Assets	5905	5872	
Intangibles	15507	16142	
Total Assets	42953	42514	
Payables	1542	1778	
Short-Term Debt	3173	4582	
Current Liabilities	9507	10823	
Long-Term Debt	3388	3719	
Total Liabilities	17782	19626	
Total Equity	25171	22888	

Valuation Analysis				
	Current	5 Yr Avg	Ind	Mkt
Price/Earnings	34.1	18.5	83.3	18.6
Forward P/E	18.6	—	—	18.9
Price/Cash Flow	16.6	11.8	24.6	11.5
Price/Free Cash Flow	22.6	15.3	34.4	10.6
Dividend Yield %	2.0	2.9	0.6	2.1
Price/Book	2.9	3.4	3.7	2.7
Price/Sales	3.0	2.5	4.0	3.4
PEG Ratio	2.4	—	—	2.2

*3Yr Avg data is displayed in place of 5 Yr Avg

Morningstar Rating	Fair Value	Fair Value	Economic Moat	Style	Sector
★★★ As of 11-17-2014	Uncertainty Low	\$44.00	Narrow	Large Growth	Health Care



2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	YTD	Stock Performance
8.8	-13.2	26.5	17.9	-2.4	4.1	-8.1	21.3	20.1	24.1	16.3	Total Return %
-2.0	-18.1	10.7	12.4	34.5	-22.4	-23.1	19.2	4.1	-8.3	3.9	+/- Market
22.2	-29.6	35.5	5.4	20.1	-37.4	-20.2	20.6	10.2	-22.3	-21.1	+/- Industry
2.2	2.8	2.4	2.3	2.6	2.9	3.6	3.3	3.1	1.5	2.0	Dividend Yield %
34762	29266	35772	41516	39621	40071	35463	42250	49413	59339	65818	Market Cap \$Mil

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	TTM	Financials (USD)
19680	22338	22476	25914	29528	30765	35167	38851	21494	21848	22162	Revenue \$Mil
54.9	52.4	56.3	55.9	57.3	57.1	58.3	60.0	54.3	54.1	54.4	Gross Margin %
3898	4362	2042	4579	5694	6236	6088	5752	1894	2629	2896	Oper Income \$Mil
19.8	19.5	9.1	17.7	19.3	20.3	17.3	14.8	8.8	12.0	13.1	Operating Margin %
3236	3372	1717	3606	4881	5746	4626	4728	5963	2576	1969	Net Income \$Mil
2.02	2.16	1.12	2.31	3.03	3.69	2.96	3.02	3.75	1.50	1.28	Earnings Per Share \$
1.03	1.09	1.16	1.27	1.41	1.56	1.72	1.88	2.01	0.56	0.80	Dividends \$
1571	1564	1537	1560	1561	1547	1556	1567	1592	1574	1538	Shares Mil
9.20	9.29	9.16	11.51	11.27	14.73	14.66	15.56	16.95	16.26	15.20	Book Value Per Share \$
4467	5174	5329	5184	6995	7275	8736	8970	9314	3324	4062	Oper Cash Flow \$Mil
-1292	-1207	-1338	-1656	-1288	-1089	-1015	-1492	-1795	-1145	-1093	Cap Spending \$Mil
3175	3967	3991	3528	5707	6186	7721	7479	7519	2179	2969	Free Cash Flow \$Mil

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	TTM	Profitability
11.8	11.7	5.3	9.5	11.9	12.1	8.2	7.8	9.4	4.7	4.5	Return on Assets %
23.6	23.5	12.1	22.7	27.7	28.5	20.3	20.1	23.3	9.9	8.5	Return on Equity %
0.72	0.77	0.69	0.68	0.72	0.65	0.62	0.64	0.34	0.40	0.51	Asset Turnover
16.4	15.1	7.6	13.9	16.5	18.7	13.2	12.2	27.7	11.8	8.9	Net Margin %
2.0	2.0	2.6	2.2	2.4	2.3	2.7	2.5	2.5	1.7	1.9	Financial Leverage

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	09-14	Financial Health (USD)
4788	4572	7010	9488	8713	11266	12524	12040	18085	3388	3719	Long-Term Debt \$Mil
14326	14415	14054	17779	17480	22856	22677	24440	26721	25171	22888	Total Equity \$Mil
0.33	0.32	0.50	0.53	0.50	0.49	0.55	0.49	0.68	0.13	0.16	Debt/Equity
3909	3971	-669	4939	5451	10264	5055	8289	18043	9740	5641	Working Capital \$Mil

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	TTM	Valuation
23.1	18.2	43.5	24.3	17.6	14.6	16.2	18.6	17.5	25.6	34.1	Price/Earnings
0.0	—	—	0.0	0.0	0.0	0.0	—	0.0	0.0	1.8	P/E vs. Market
3.7	2.8	3.3	3.4	2.8	2.7	2.1	2.3	2.6	2.8	3.0	Price/Sales
5.1	4.2	5.3	4.9	4.7	3.7	3.3	3.6	3.9	2.4	2.9	Price/Book
16.6	11.9	14.0	16.9	11.3	11.5	8.5	9.8	11.2	18.1	16.6	Price/Cash Flow

Quarterly Results (USD)				
Revenue \$Mil	Dec	Mar	Jun	Sep
Most Recent	7205.0	5244.0	5551.0	5104.0
Previous	5632.0	5378.0	5446.0	4825.0
Rev Growth %	Dec	Mar	Jun	Sep
Most Recent	27.9	-2.5	1.9	5.8
Previous	-45.7	1.8	2.5	-8.4
Earnings Per Share \$	Dec	Mar	Jun	Sep
Most Recent	0.38	0.22	0.30	0.29
Previous	0.66	0.34	0.30	0.49

Close Competitors				
Company	Mkt Cap \$Mil	Rev \$Mil	P/E	ROE%
Johnson & Johnson	303144	74432	18.0	23.7
Mead Johnson Nutrition Co	20344	4376	30.0	188.9

Major Fund Holders		% of shares
Vanguard Total Stock Mkt Idx		1.63
Vanguard 500 Index Inv		1.04
Vanguard Institutional Index I		1.01

©2014 Morningstar. All Rights Reserved. The information, data, analyses and opinions contained herein (1) include the confidential and proprietary information of Morningstar, (2) may include, or be derived from, account information provided by your financial advisor which cannot be verified by Morningstar, (3) may not be copied or redistributed, (4) do not constitute investment advice offered by Morningstar, (5) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (6) are not warranted to be correct, complete or accurate. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, this information, data, analyses or opinions or their use. This report is supplemental sales literature. If applicable it must be preceded or accompanied by a prospectus, or equivalent, and disclosure statement.

